ADMA Biologics Q2 revenues up 38%

|About: ADMA Biologics Inc (ADMA)|By:, SA News Editor

ADMA Biologics (ADMA) Q2 results: Revenues: $4.7M (+38.2%); Product revenue: $4.6M (+35.3%); License and other revenue: $0.04M (unch).

Net Loss: ($14.7M) (-63.3%); Loss Per Share: ($0.35) (+36.4%).

2018 & 2019 Anticipated Goals and Milestones: BIVIGAM PDUFA target action date is October 25.

Respond to complete response letter and resubmit BLA for RI-002.

Obtain FDA approval for 3rd plasma collection center.

Commercial and promotional launch for RI-002.

Expand promotional activities for Nabi-HB.

Subscribe for full text news in your inbox